دورية أكاديمية

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

التفاصيل البيبلوغرافية
العنوان: Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
المؤلفون: Tawbi, Hussein A., Hodi, F. Stephen, Lipson, Evan J., Schadendorf, Dirk, Ascierto, Paolo Antonio, Matamala, Luis, Gutiérrez, Erika Castillo, Rutkowski, Piotr, Gogas, Helen, Lao, Christopher D., Janoski De Menezes, Juliana, Dalle, Stéphane, Arance, Ana Maria, Grob, Jean-Jacques, Ratto, Barbara, Rodriguez, Saima, Xu, Yuanfang, Dolfi, Sonia, Long, Georgina V.
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9502-9502, 1p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2023.41.16_suppl.9502